JP2020529440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529440A5 JP2020529440A5 JP2020505905A JP2020505905A JP2020529440A5 JP 2020529440 A5 JP2020529440 A5 JP 2020529440A5 JP 2020505905 A JP2020505905 A JP 2020505905A JP 2020505905 A JP2020505905 A JP 2020505905A JP 2020529440 A5 JP2020529440 A5 JP 2020529440A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- acceptable salt
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 10
- 239000003472 antidiabetic agent Substances 0.000 claims 6
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 208000030159 metabolic disease Diseases 0.000 claims 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 239000008103 glucose Substances 0.000 claims 4
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 claims 3
- 229950004346 gaboxadol Drugs 0.000 claims 3
- 201000002859 sleep apnea Diseases 0.000 claims 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 2
- 229940123208 Biguanide Drugs 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 208000001280 Prediabetic State Diseases 0.000 claims 2
- 229940100389 Sulfonylurea Drugs 0.000 claims 2
- 229940123464 Thiazolidinedione Drugs 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 2
- 150000004283 biguanides Chemical class 0.000 claims 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 238000007410 oral glucose tolerance test Methods 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 150000001467 thiazolidinediones Chemical class 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541260P | 2017-08-04 | 2017-08-04 | |
| US62/541,260 | 2017-08-04 | ||
| PCT/US2018/044973 WO2019028234A1 (en) | 2017-08-04 | 2018-08-02 | USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020529440A JP2020529440A (ja) | 2020-10-08 |
| JP2020529440A5 true JP2020529440A5 (enExample) | 2021-09-09 |
Family
ID=65230918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505905A Pending JP2020529440A (ja) | 2017-08-04 | 2018-08-02 | 糖尿病および関連する状態の処置におけるガボキサドールの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10813918B2 (enExample) |
| EP (1) | EP3648762A4 (enExample) |
| JP (1) | JP2020529440A (enExample) |
| KR (1) | KR20200047557A (enExample) |
| CN (1) | CN111201022A (enExample) |
| AU (1) | AU2018309049A1 (enExample) |
| CA (1) | CA3071939A1 (enExample) |
| IL (1) | IL272414A (enExample) |
| MX (1) | MX2020001342A (enExample) |
| WO (1) | WO2019028234A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3071939A1 (en) | 2017-08-04 | 2019-02-07 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of diabetes and related conditions |
| KR20200069316A (ko) | 2017-10-12 | 2020-06-16 | 노보 노르디스크 에이/에스 | 의료 요법에서의 세마글루타이드 |
| MX2021005992A (es) | 2018-11-21 | 2021-09-14 | Certego Therapeutics Inc | Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión. |
| MX2022007715A (es) | 2019-12-18 | 2022-07-19 | Ovid Therapeutics Inc | Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36. |
| IL298334A (en) | 2020-05-20 | 2023-01-01 | Certego Therapeutics Inc | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
| EP4511030A2 (en) * | 2022-04-20 | 2025-02-26 | Aclipse Two Inc. | Treatment of gastrointestinal diseases |
| WO2025049710A1 (en) * | 2023-08-29 | 2025-03-06 | Aclipse Two Inc. | Pharmaceutical composition for use in the disease treatments |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270278A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Cycliske aminosyrer |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4353910A (en) | 1981-11-27 | 1982-10-12 | Kefalas A/S | Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment |
| DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| MXPA06011325A (es) | 2004-04-02 | 2006-12-15 | Lundbeck & Co As H | Tratamiento de la funcion respiratoria alterada con gaboxadol. |
| EA200601853A1 (ru) * | 2004-04-02 | 2007-02-27 | Х. Лундбекк А/С | Лечение нарушенной дыхательной функции |
| WO2006102093A1 (en) * | 2005-03-18 | 2006-09-28 | Transform Pharmaceuticals, Inc. | Gaboxadol forms, compositions thereof, and related methods |
| DE102005020882A1 (de) * | 2005-05-04 | 2006-11-09 | Dömling, Alexander, Dr. | Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten |
| US20110046090A1 (en) | 2005-10-31 | 2011-02-24 | Braincells Inc. | Modulation of neurogenesis with gaba agents and gaba analogs |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US7635710B2 (en) | 2006-02-15 | 2009-12-22 | Neurim Pharmaceuticals (1991) Ltd. | Pyrone-indole derivatives and process for their preparation |
| RS55585B1 (sr) | 2006-11-22 | 2017-06-30 | Clinical Research Associates LLC | Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma |
| TW200920358A (en) | 2007-08-13 | 2009-05-16 | Lundbeck & Co As H | Method of treating stress-mediated depression |
| US20090143335A1 (en) | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
| WO2009117367A1 (en) * | 2008-03-18 | 2009-09-24 | Bristol-Myers Squibb Company | Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof |
| WO2012050907A2 (en) * | 2010-09-28 | 2012-04-19 | The Regents Of The University Of California | Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes |
| WO2013024047A1 (en) * | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
| PT3151832T (pt) | 2014-06-06 | 2021-06-15 | Ovid Therapeutics Inc | Métodos para aumentar a inibição tónica e tratar a insónia secundária |
| JP6491679B2 (ja) | 2014-06-12 | 2019-03-27 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | Ｇａｂａａ受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体 |
| US10610504B2 (en) * | 2014-12-23 | 2020-04-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Alpha-cell re-generation combined with conversion to beta cells |
| AU2016295138B2 (en) | 2015-07-17 | 2021-11-04 | Ovid Therapeutics Inc. | Methods of treating developmental disorders with gaboxadol |
| US9682069B2 (en) * | 2015-07-17 | 2017-06-20 | Ovid Therapeutics Inc | Methods of treating Dravet syndrome |
| US20170348232A1 (en) | 2016-06-07 | 2017-12-07 | Ovid Therapeutics Inc. | Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome |
| US9399034B1 (en) | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
| US9351968B1 (en) | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
| US20180042903A1 (en) | 2016-08-11 | 2018-02-15 | Ovid Therapeutics Inc. | Methods and compositions for treatment of epileptic disorders |
| CA3071939A1 (en) | 2017-08-04 | 2019-02-07 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of diabetes and related conditions |
-
2018
- 2018-08-02 CA CA3071939A patent/CA3071939A1/en active Pending
- 2018-08-02 EP EP18840846.2A patent/EP3648762A4/en not_active Withdrawn
- 2018-08-02 WO PCT/US2018/044973 patent/WO2019028234A1/en not_active Ceased
- 2018-08-02 JP JP2020505905A patent/JP2020529440A/ja active Pending
- 2018-08-02 US US16/053,081 patent/US10813918B2/en not_active Expired - Fee Related
- 2018-08-02 KR KR1020207006304A patent/KR20200047557A/ko not_active Withdrawn
- 2018-08-02 AU AU2018309049A patent/AU2018309049A1/en not_active Abandoned
- 2018-08-02 MX MX2020001342A patent/MX2020001342A/es unknown
- 2018-08-02 CN CN201880065399.8A patent/CN111201022A/zh active Pending
-
2020
- 2020-02-02 IL IL272414A patent/IL272414A/en unknown
- 2020-10-08 US US17/066,389 patent/US11291658B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529440A5 (enExample) | ||
| JP4846063B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| CA2724133C (en) | Medicine consisting of concomitant use or combination of dpp-iv inhibitor and other diabetic medicine | |
| JP6066144B2 (ja) | 併用医薬 | |
| TW202202139A (zh) | 以２－〔（４－｛６－〔（４－氰基－２－氟苄基）氧基〕吡啶－２－基｝哌啶－１－基）甲基〕－１－〔（２ｓ）－氧雜環丁烷－２－基甲基〕－１ｈ－苯並咪唑－６－甲酸或其藥學上的鹽治療第２型糖尿病或肥胖症或體重過重 | |
| CN105407879A (zh) | 与帕金森病治疗相关的副作用的治疗 | |
| JP2018509419A5 (enExample) | ||
| JP2024019691A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
| TW202435860A (zh) | 用於治療疼痛的ｒ—ｍｄｍａ | |
| CN1921881A (zh) | 羟基化氨基酸用于治疗糖尿病的用途 | |
| JP2021001221A (ja) | 精神障害の治療における使用のためのイロペリドン代謝物 | |
| JP6692903B2 (ja) | 高血糖症を処置する方法 | |
| JP6550160B2 (ja) | 糖尿病及び関連症状の治療のための方法及び組成物 | |
| TW201210586A (en) | Methods of using diacerein as an adjunctive therapy for diabetes | |
| WO2006116470A1 (en) | Use of metformin to counteract weight gain associated with aripiprazole or ziprasidone treatment | |
| JP2006508118A5 (enExample) | ||
| JPWO2007007757A1 (ja) | ＰＰＡＲγアゴニストを含有する医薬組成物 | |
| CA3100635A1 (en) | Combinations comprising tropifexor and cenicriviroc | |
| WO2011002012A1 (ja) | Sglt1阻害薬とインスリン抵抗性改善薬を組み合わせてなる医薬 | |
| US7608625B2 (en) | Method for treating bruxism and bruxism-related diseases | |
| JP2009513593A (ja) | 糖尿病の治療 | |
| TWI461192B (zh) | 降低血脂異常病患之糖化血色素的醫藥組成物 | |
| WO2012133693A1 (ja) | 糖尿病治療用の組合せ医薬 | |
| CN1972715A (zh) | 含有胰岛素抵抗改善剂的糖尿病治疗剂 | |
| JP2005314380A5 (enExample) |